Hengeler Mueller advises shareholders of TIB Molbiol on sale to Roche

F. Hoffmann-La Roche announced that it has signed a definitive share purchase agreement to acquire all outstanding shares of the TIB Molbiol Group. TIB Molbiol is a medium-sized biotech company headquartered in Berlin (Germany) and has local representations in Australia, Colombia, Italy, Spain and the US. It has supplied the global market with reagents for research and medical diagnostics for over 30 years. Closing of the transaction is subject to customary conditions and is expected in the fourth quarter of 2021.

Hengeler Mueller advised the shareholders of TIB Mobil Group on the transaction. The team was led by partner Kai-Steffen Scholz (M&A/Corporate) and included partners Wolfgang Spoerr, Jan Bonhage (both Regulatory) (all Berlin), Markus Ernst (Tax, Munich), Hendrik Bockenheimer (Employment, Frankfurt) and Christoph Stadler (Antitrust, Düsseldorf), counsel Alexander Bekier, Marvin Vesper-Gräske (both M&A/Corporate), Matthias Berberich (IP/IT) (all Berlin) as well as associates Niclas Bettien (M&A/Corporate, Berlin), Michael Schramm (Düsseldorf), Wiebke Lemmer, Anton O. Petrov (both Berlin) (all Regulatory), Tim Würstlin (Tax, Munich), Selina Rohr (Employment, Frankfurt), Cornelia Gersch (IP/IT, Berlin) and Christian Dankerl (Antitrust, Düsseldorf).